Collaborations

Collaboration inked for trial for the treatment of critical limb ischemia with VEGF-2

Published in Cardiovascular Week, January 30th, 2006

Corautus Genetics, Inc., (VEGF) announced that it has entered into an agreement through which it will support the clinical trial of Caritas St. Elizabeth's Medical Center of Boston (Massachusetts) (CSEMC) evaluating the safety and efficacy of vascular endothelial growth factor (VEGF)-2 for the treatment of patients suffering with moderate or high-risk critical limb ischemia (CLI).

Under the agreement, Corautus will provide its proprietary vascular endothelial growth factor, VEGF-2, to CSEMC for evaluation in a 64-patient, phase I trial for the treatment of CLI. CSEMC is the sponsor of this clinical trial which will be conducted under a funding grant from the U.S....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Week

Source: Cardiovascular Week (2006-01-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry